

SELECTION of PUBLICATIONS ON RGTA TECHNOLOGY

2012

Tong et al, Diabetes-Impaired Wound Healing Is Improved by Matrix Therapy with Heparan Sulfate Glycosaminoglycan Mimetic OTR4120 in Rats, Diabetes [accepted for publication] [93]

Al MAIaq A, BARRITault Denis, A rapid response to matrix therapy with RGTA® in severe epidermolysis bullosa – Eplasty 2012 [92]

Slim et al, Matrix Protection Therapy in Diabetic foot Ulcers : Pilot Study of Caciqliq20, JOURNAL OF WOUND TECHNOLOGY No. 17 p16 JULY 2012 [91]

Van Neck et al, Heparan sulfate proteoglycan mimetics thrive tissue regeneration: an overview. In Intech book under the working title "Tissue Regeneration", [ISBN 978-953-307-876-2](#) [87]

Spiegelberg L, et al, The effects of heparan sulphate mimetic RGTA-OTR4120 on irradiated murine salivary glands. J Oral Pathol Med. 2012 Jan 10. [Epub ahead of print] [86]

2011

First Clinical Pilot Study on critical ischemic leg ulcers with Matrix Therapy ReGeneraTing Agent (RGTA®) technology P. Desgranges, T. Louissaint, E. Allaire, B. Godeau, K. Kichenin, J.- P. Becquemin , D. Barritault , _ JOURNAL OF WOUND TECHNOLOGY No. 13 p47 4JULY 2011 [83]

Van Neck JW, Zuidema YS, Smulders M, Balmus KJ .Unexpected healing of radiation-induced scalp lesions with OTR4120, a heparan sulfate mimetic. Van Neck JW, Zuidema YS, Smulders M, Balmus KJ. Eur J Dermatol. 2011 May 20. [84]

ReGeneraTing Agents Matrix Therapy Regenerates a Functional Root Attachment in Hamsters with Periodontitis. Lallam-Laroye C, [Baroukh B](#), [Doucet P](#), [Barritault D](#), [Saffar JL](#), Colombier ML. Tissue Eng Part A. 2011 Jun 20. [Epub ahead of print]

Miao Tong, MD ; Bastiaan Tuk ; Ineke M. Hekking ; Mieke M. Pleurmeekers, MD ; Mireille B. Boldewijn, MD ; Steven E.R. Hovius, MD, PhD ; Hohan W.van Neck, PhD. Heperan Sulfacte glycosaminoglycan mometic improves pressure ulcer Healing in a rat model of cutaneous ischemia-reperfusion injury. Wound Rep, Reg (2011) 1-10 [82]

Zakine G, Barbier V, Garcia-Filipe S, Luboinski J, Papy-Garcia D, Chachques JC, Carpentier A, Barritault D. Matrix therapy with RGTA OTR4120 improves healing time and quality in hairless rats with deep second-degree burns. Plast Reconstr Surg. 2011 Feb;127(2):541-50. [85]

Suzanne L Groah^{1,*}, Alexander Libin², Miriam Spungen³, Kim-Loan Nguyen⁴, Earthaleen Woods⁵, Marjan Nabili⁶, Jessica Ramella-Roman⁷, Denis Barritault⁸. Regenerating matrix-based therapy for chronic wound healing: a prospective within-subject pilot study
International Wound Journal Volume 8, Issue 1, pages 85–95, February [81]

2010

Barritault D, Garcia-Filipe S, Zakine G. [Basement of matrix therapy in regenerative medicine by RGTA(®): From fundamental to plastic surgery]. *Ann Chir Plast Esthet*. 2010 Oct;55(5):413-20. French

Zakine G, Le Louarn C. [First applications of matrix therapy in plastic and aesthetic surgery]. *Ann Chir Plast Esthet*. 2010 Oct;55(5):421-8. Epub 2010 Sep 24. Frenc [80]

Charef S, Tulliez M, Esmilaire L, Courty J, Papy-Garcia D. Toxicological evaluation of RGTA OTR4120, a heparan sulfate mimetic. *Food Chem Toxicol*. 2010 Jul;48(7):1965-8. Epub 2010 May 7.

Martelly I, Singabraya D, Vandebrouck A, Papy-Garcia D, Cognard C, Raymond G, Guillet-Deniau I, Courty J, Constantin B. Glycosaminoglycan mimetics trigger IP3-dependent intracellular calcium release in myoblasts. *Matrix Biol*. 2010 May;29(4):317-29. Epub 2010 Mar 1

2009

Tong M, Tuk B, Hekking I, Vermeij M, Barritault D, Van Neck J. Stimulated neovascularization, inflammation resolution and collagen maturation in healing rat cutaneous wounds by a heparan sulfate glycosaminoglycan mimetic, OTR4120. *Wound Rep Reg* (2009) 17 840–852 [69]

*Yue X-L, Lehri S, Li P, Barbier-Chassefière V, Petit V, Huang Q-F, Albanese P, Barritault D, Caruelle J-P, Papy-Garcia D and Morin C. Insights on a new path of pre-mitochondrial apoptosis regulation by a glycosaminoglycan mimetic. *Cell Death and Differentiation* (2009), 1–12 [73]

*Mangoni M, Yue XL, Morin C, Violot D, Frascogna V, Tao YG, Caruelle JP, Huang QF, Li P, Barritault D, Biti G and Bourhis J. An heparan-mimetic of the RGTA family protects mice from radiation-induced mucositis. *Int. J. Radiation Oncology Biol. Phys.* 2009,74,1242-1250. [68]

*Barbier-Chassefière V, Garcia-Filipe S, Yue XI, Kerros Me, Petit E, Kern P, Saffar JI, Papy-Garcia D, Caruelle JP and Barritault D : Matrix Therapy and regenerative medicine, a new approach for chronic wound healing **J. Bio Mater. Res A**. 2009,90,641-647. [65]

2008

Khammari-Chebba CK, Kichenin K, Amar N, Nourry H, Warnet JM, Barritault D, Baudouin C. Pilot study of a new matrix therapy agent (RGTA OTR4120) in treatment-resistant corneal ulcers and corneal dystrophy, **J Fr Ophthalmol**. 2008 May;31(5):465-71 [66]

*Mischa Zuijendorp, H, Smit X, de Kool S, Blok J, Jean Pierre Caruelle, Denis Barritault, Hovius S, van Neck J RGTA, a Synthetic Glycosaminoglycan Mimetic, Significantly Reduces Neural Adhesions after Peripheral Nerve Injury in Rats , **Neurosurg**. 2008 Nov;109(5):967-73 [72]

Tong M, Zbinden MM, Hekking IJ, Vermeij M, Barritault D, van Neck JWRGTA OTR 4120, a heparan sulphate proteoglycan mimetic, increases wound breaking strength and vasodilatory capability in healing rat full-thickness excisional wounds. **Wound Repair and Regeneration** , 2008, 16, 294-299 [63]

2007

Charef S, Petit E, Barritault D, Courty J, Caruelle JP. Effects on coagulation of a synthetic heparan mimetic given intraperitoneally or orally. **J Biomed Mater Res A**. 2007 83(4):1024-31.

Ouidja Mohand-O, Petit E, Kerros M.E, Ikeda Y ; Carpentier G ; Barritault D, Brugère-Picoux J , Deslys JP, PAPHY-GARCIA D Structure-Activity Studies of Heparan Mimetics Polyanions for Anti-Prion Therapies, **BBRC** 2007, 363, 95-100

Larramendy-Goizalo C, Barret A, Daudigeos E, Mathieu E, Antonangeli L, Riffet C, Petit E, Papy-Garcia D, Barritault D, Brown P, Deslys JP. Comparison of CR36, a new heparan mimetic, and pentosan polysulfate in the treatment of prion diseases. **J Gen Virol**. 2007, 88:1062-7.

Sutton A, Friand V, Papy-Garcia D, Dagouassat M, Martin L, Vassy R, Haddad O, Sainte-Catherine O, Kraemer M, Saffar L, Perret GY, Courty J, Gattegno L, Charnaux N. Glycosaminoglycans and their synthetic mimetics inhibit RANTES-induced migration and invasion of human hepatoma cells. **Mol Cancer Ther**. 2007, 6(11):2948-58.

*Rouet ,V, Meddahi-Pellé A, Miao Hua-Quan , Vlodaysky I , Caruelle J. P , Barritault D Heparin-like synthetic polymers, named RGTAs, mimic biological effects of heparin in vitro. **J. Bio Mater. Res**. 2007, 80 :75-84. [55]

Garcia-Filipe S, Barbier-Chassefiere V, Alexakis C, Huet C, Ledoux D, Kerros ME, Petit E, Barritault D, Caruelle JP, Kern P. RGTA OTR4120, a heparan sulfate mimetic is a possible long-term active agent to heal burned skin." **J. Bio Mater. Res**. 75-84, 2007 [53]

2006

Sabine Gauczynski, Daphne Nikles, Susanne El-Gogo, Dulce Papy-Garcia, Clémence Rey1, Susanne Alban, Denis Barritault, Corinne Ida Lasmézas and Stefan Weiss. Binding of infectious prions to the 37 kDa/67 kDa laminin receptor is inhibited by polysulfated glycosaminoglycans **J. infect. Disease**. 2006 194 :702-9

Corinne Lallam-Laroye, Quentin Escartin, Aude-Sophie Zlowodzki, Denis Barritault, Jean-Pierre Caruelle, Brigitte Baroukh, Jean-Louis Saffar, and Marie-Laure Colombier. Periodontitis destructions are restored by synthetic glycosaminoglycan mimetic **J. Bio Mater. Res.** 2006 79A,675-83. [58]

Barritault D, Caruelle JP. Regenerating agents (RGTA): a new therapeutic approach *Ann Pharm Fr.* 2006 Mar;64(2):135-44. Review. French. [59]

DeCarlo A.A.; Whitelock J.M. The Role of Heparan Sulfate and Perlecan in Bone-regenerative Procedures *J Dent Res* 85(2):122-132, 2006 [86]

2005

*Rouet V, Hamma-Kourbali Y, Petit E, Panagopoulou P, Katsoris P, Barritault D, Caruelle JP, Courty J. A synthetic glycosaminoglycan mimetic binds vascular endothelial growth factor and modulates angiogenesis. **J Biol Chem.** 2005 280(38):32792-800 [54]

Barbosa I, Morin C, Garcia S, Duchesnay A, Oudghir M, Jenniskens G, Miao HQ, Guimond S, Carpentier G, Cebrian J, Caruelle JP, van Kuppevelt T, Turnbull J, Martelly I, Papy-Garcia D. "A synthetic glycosaminoglycan mimetic (RGTA) modifies natural glycosaminoglycan species during myogenesis" **J Cell Sci.** 2005; 118(Pt 1):253-64. [76]

Horonchik L, Tzaban S, Ben-Zaken O, Yedidia Y, Rouvinski A, Papy-Garcia D, Barritault D, Vlodavsky I, Taraboulos. "A Heparan sulfate is a cellular receptor for purified infectious prions". **J Biol Chem.** 2005; 280(17):17062-7..

Zimowska M, Constantin B, Papy-Garcia D, Raymond G, Cognard C, Caruelle JP, Moraczewski J, Martelly I. "Novel glycosaminoglycan mimetic (RGTA, RGD120) contributes to enhance skeletal muscle satellite cell fusion by increasing intracellular Ca(2+) and calpain activity". **J Cell Physiol.** 2005 May 10

2004

Alexakis C, Caruelle JP, Sezeur A, Cosnes J, Gendre JP, Mosnier H, Beaugerie L, Gallot D, Malafosse M, Barritault D, Kern P. "Reversal of abnormal collagen production in Crohn's disease intestinal biopsies treated with regenerating agents". **Gut. 2004 Jan; 53(1):85-90. [44]

*Alexakis C, Mestries P, Garcia S, Petit E, Barbier V, Papy-Garcia D, Sagot MA, Barritault D, Caruelle JP, Kern P. "Structurally different RGTAs modulate collagen-type expression by cultured aortic smooth muscle cells via different pathways involving fibroblast growth factor-2 or transforming growth factor-beta1". **FASEB J.** 2004 Jul; *18(10)*:1147-9. [47]

Alexakis C, Strup C, Mestries P, Mathe D, Caruelle JP, Barritault D, Kern P. "Regulation of the collagen phenotype expression of gamma-irradiated vascular smooth muscle cells by heparan mimetics (RGTA)". **J Biomed Mater Res A.** 2004 Sep 15; *70(4)*:594-602. [46]

Lafont J, Blanguaert F, Colombier ML, Barritault D, Caruelle JP, Saffar JL. "Kinetic study of early regenerative effects of RGTA11, a heparan sulfate mimetic, in rat craniotomy defects". **Calcif Tissue Int.** 2004 Dec; *75(6)*:517-25. [49]

Morvan FO, Baroukh B, Ledoux D, Caruelle JP, Barritault D, Godeau G, Saffar JL. "An engineered biopolymer prevents mucositis induced by 5-fluorouracil in hamsters". **Am J Pathol. 2004 Feb; *164(2)*:739-46. [63]

Petit E, Papy-Garcia D, Muller G, Courtois B, Caruelle JP, Courtois J. "Controlled sulfatation of natural anionic bacterial polysaccharides can yield agents with specific regenerating activity in vivo". **Biomacromolecules.** 2004 Mar-Apr; *5(2)*:445-52.

2003

Adjou KT, Simoneau S, Sales N, Lamoury F, Dormont D, Papy-Garcia D, Barritault D, Deslys JP, Lasmezas Cl. "A novel generation of heparan sulfate mimetics for the treatment of prion diseases". **J Gen Virol.** 2003 Sep; *84(Pt 9)*:2595-603. [77]

Barbosa I, Garcia S, Barbier-Chassefiere V, Caruelle JP, Martelly I, Papy-Garcia D. "Improved and simple micro assay for sulfated glycosaminoglycans quantification in biological extracts and its use in skin and muscle tissue studies". **Glycobiology.** 2003 Sep; *13(9)*:647-53. Epub 2003 May 28.

Blanguaert F, Carpentier G, Morvan F, Caruelle JP, Barritault D, Tardieu M. "RGTA modulates the healing pattern of a defect in a monolayer of osteoblastic cells by acting on both proliferation and migration". **J Biomed Mater Res.** 2003 Mar 1; *64(3)*:525-32. [43]

*Escartin Q, Lallam-Laroye C, Baroukh B, Morvan FO, Caruelle JP, Godeau G, Barritault D, Saffar JL. "A new approach to treat tissue destruction in periodontitis with chemically modified dextran polymers". **FASEB J.** 2003 Apr; *17(6)*:644-51. [37]

Ledoux D, Merciris D, Barritault D, Caruelle JP. « Heparin-like dextran derivatives as well as glycosaminoglycans inhibit the enzymatic activity of human cathepsin G". **FEBS Lett.** 2003 Feb 27; *537(1-3)*:23-9. [39]

Li P, Cebrian J, Carpentier G, Barbosa I, Barritault D. "Effect of RG1192, a substituted dextran, on inflammatory response". **Cell Mol Biol** 2003; *49* [38]

Schonberger O, Horonchik L, Gabizon R, Papy-Garcia D, Barritault D, Taraboulos A. "Novel heparan mimetics potently inhibit the scrapie prion protein and its endocytosis". **Biochem Biophys Res Commun**. 2003 Dec 12; 312(2):473-9.

Zakine G, Martinod E, Fornes P, Sapoval M, Barritault D, Carpentier AF, Chachques JC. "Growth factors improve latissimus dorsi muscle vascularization and trophicity after cardiomyoplasty". **Ann Thorac Surg**. 2003 Feb; 75(2):549-54. [40]

2002

Meddahi A, Alexakis C, Papy D, Caruelle JP, Barritault D. "Heparin-like polymer improved healing of gastric and colic ulceration". **J Biomed Mater Res**. 2002, 60(3):497-501. [34]

Meddahi A, Bree F, Papy-Garcia D, Gautron J, Barritault D, Caruelle JP. "Pharmacological studies of RGTA(11), a heparan sulfate mimetic polymer, efficient on muscle regeneration". **J Biomed Mater Res**. 2002, 62(4):525-31. [36]

Papy-Garcia D, Barbosa I, Duchesnay A, Saadi S, Caruelle JP, Barritault D, Martelly I. "Glycosaminoglycan mimetics (RGTA) modulate adult skeletal muscle satellite cell proliferation in vitro". **J Biomed Mater Res**. 2002, 62(1):46-55. [33]

2001

Alexakis C, Guettoufi A, Mestries P, Strup C, Mathe D, Barbaud C, Barritault D, Caruelle JP, Kern P. "Heparan mimetic regulates collagen expression and TGF-beta1 distribution in gamma-irradiated human intestinal smooth muscle cells". **FASEB J**. 2001 Jul; 15(9):1546-54. [30]

Desgranges P, Caruelle JP, Carpentier G, Barritault D, Tardieu M. "Beneficial use of fibroblast growth factor 2 and RGTA, a new family of heparan mimics, for endothelialization of PET prostheses". **J Biomed Mater Res**. 2001; 58(1):1-9.

Mestries P, Alexakis C, Papy-Garcia D, Duchesnay A, Barritault D, Caruelle JP, Kern P. "Specific RGTA increases collagen V expression by cultured aortic smooth muscle cells via activation and protection of transforming growth factor-beta1". **Matrix Biol**. 2001 Jun; 20(3): 171-81. [31]

Zimowska M, Szczepankowska D, Streminska W, Papy D, Tournaire MC, Gautron J, Barritault D, Moraczewski J, Martelly I. "Heparan sulfate mimetics modulate calpain activity during rat Soleus muscle regeneration". **J Cell Physiol**. 2001,188(2):178-87. [32]

2000

Jeanbat-Mimaud V, Barbaud C, Caruelle JP, Barritault D, Cammas-Marion S, Langlois V, Guerin P. "Bioactive functionalized polymer of malic acid for bone repair and muscle regeneration". **J Biomater Sci Polym Ed**. 2000; 11(9):979-91.

*Ledoux D, Papy-Garcia D, Escartin Q, Sagot MA, Cao Y, Barritault D, Courtois J, Hornebeck W, Caruelle JP. "Human plasmin enzymatic activity is inhibited by chemically modified dextrans". **J Biol Chem**. 2000, 275(38):29383-90. [27]

*Yamauchi H, Desgranges P, Lecerf L, Papy-Garcia D, Tournaire MC, Moczar M, Loisan D, Barritault D. "New agents for the treatment of infarcted myocardium". **FASEB J**. 2000 (14): 2133-4.

1999

Blanquaert F, Barritault D, Caruelle JP. "Effects of heparan-like polymers associated with growth factors on osteoblast proliferation and phenotype expression". **J Biomed Mater Res**. 1999 Jan; 44(1):63-72. [10] [23]

Colombier ML, Lafont J, Blanquaert F, Caruelle JP, Barritault D, Saffar JL. "A single low dose of RGTA, a new healing agent, hastens wound maturation and enhances bone deposition in rat craniotomy defects". **Cells Tissues Organs**. 1999; 164(3):131-40.

*Desgranges P, Barbaud C, Caruelle JP, Barritault D, Gautron J. "A substituted dextran enhances muscle fiber survival and regeneration in ischemic and denervated rat EDL muscle". **FASEB J**. 1999 Apr; 13(6):761-6. [21]

Stockholm D, Barbaud C, Marchand S, Ammarguella F, Barritault D, Richard I, Beckmann J, Martelly I. "Studies on calpain expression during differentiation of rat satellite cells in primary cultures in the presence of heparin or a mimic compound". **Exp Cell Res**. 1999, 252(2):392-400.

* Major Publications